Examkin

Question

Difficulty: HardResearch Ethics and Conflicts of Interest

A third-year internal medicine resident is completing a research rotation under the supervision of a prominent Principal Investigator (PI). The PI is leading an industry-sponsored, phase III randomized controlled trial evaluating a novel biologic agent for severe rheumatoid arthritis. While reviewing patient charts in preparation for an upcoming monitoring visit, the resident discovers that the PI recently enrolled three patients who had a documented history of latent tuberculosis. According to the study guidelines, a history of latent tuberculosis is a strict exclusion criterion due to the risk of fatal reactivation. All three patients have already received their first dose of the experimental biologic. Arrange the following steps in the most appropriate ethical and regulatory sequence of escalation for managing this suspected protocol violation.

  1. 1Cross-reference the patients' primary medical records with the approved study protocol to verify the exact exclusion criteria.
  2. 2Discuss the discrepancies directly with the Principal Investigator to seek clarification and request immediate corrective action.
  3. 3Report the protocol violation to the Institutional Review Board (IRB) if the Principal Investigator dismisses the concern or refuses to act.
  4. 4The Institutional Review Board conducts an expedited review and temporarily suspends the clinical trial to protect enrolled subjects.
  5. 5The institution officially reports the trial suspension and protocol violations to the trial sponsor and federal regulatory authorities.

Answer

The correct sequence begins with the resident verifying the facts, followed by discussing the issue with the Principal Investigator. If the PI is unresponsive, the resident must report to the IRB. The IRB then suspends the trial, and finally, the institution notifies federal regulators and the sponsor.
In clinical research, managing suspected protocol violations follows a strict ethical and regulatory hierarchy based on Good Clinical Practice (GCP) and the AMA Code of Medical Ethics. First, any suspicion must be objectively verified by cross-referencing primary data with the approved protocol. Second, the discovering clinician should address the issue with the Principal Investigator; this allows for immediate clinical management of the affected patients and standard deviation reporting if it was an oversight. Third, if the PI dismisses a violation that threatens patient safety, the clinician must escalate to the Institutional Review Board (IRB). Fourth, the IRB exercises its mandate to protect human subjects by suspending the non-compliant trial. Finally, institutional officials fulfill federal requirements by reporting the IRB's suspension to external entities, including the trial sponsor and the FDA/OHRP.

Step-by-Step Solution

1
Verify the facts.
The resident confirms that the patients genuinely meet exclusion criteria according to the official protocol.
Prevents false accusations based on clerical errors or misunderstandings of the protocol.
2
Address the Principal Investigator.
The resident gives the PI the opportunity to correct the error, report the deviation, and manage patient safety.
Standard professional conduct requires clarifying discrepancies with the responsible individual first, unless there is immediate imminent harm.
3
Escalate to the IRB.
The resident fulfills their ethical duty to protect patients by bypassing a non-compliant PI.
When a superior fails to act on a safety violation, the duty to patient safety supersedes institutional hierarchy.
4
IRB Intervention.
The IRB suspends the study.
The IRB is the local regulatory body tasked with ensuring the ongoing safety of human subjects in research.
5
Institutional Reporting.
The sponsor and FDA are notified of the suspension.
Federal law mandates that institutions report any unanticipated problems involving risks to subjects or suspensions of IRB approval to oversight agencies.

Key Concept

Escalation of clinical research protocol violations and human subjects protection.
Rate this question

Topics

Research Ethics and Conflicts of Interest

More questions from this topic